2 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
Follow Refractory AML: new trials by email Literature Review of Refractory AML trials Research Report on Refractory AML
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Natural Killer Cell (CYNK-001) Infusions in Adults with AML CYNK-001 - Leukemia, Leukemia, Myeloid | Phase 1 | Terminated | Celularity Incorporated | 27 | 2020-03-12 | 2024-12-12 |
| Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia GEM333 - Acute Myeloid Leukemia, Relapsed AML | Phase 1 | Terminated | AvenCell Europe GmbH | 36 | 2018-04-11 | 2022-09-29 |
Leukemia, Myeloid, Acute (2) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasm, Residual (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Hemic and Lymphatic Diseases (2) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
AvenCell Europe GmbH (1) · Celularity Incorporated (1)
Germany (1) · United States (1)
Martin Wermke, MD (1) · Sharmila Koppisetti, M.D (1)
2017 (1)